---
title: "Sirolimus - Renal Cell Carcinoma"
sidebar: mydoc_sidebar
permalink: db00877-mesh-d002292-1.html
toc: false 
---


Path ID: `DB00877_MESH_D002292_1`
{% include image.html url="images/db00877-mesh-d002292-1.png" file="db00877-mesh-d002292-1.png" alt="db00877-mesh-d002292-1" %}

## Concepts

|------------|------|---------|
| Identifier | Name | Type    |
|------------|------|---------|
| UniProt:P42345 | Serine/threonine-protein kinase mTOR | Protein |
| MESH:D020123 | Sirolimus | Drug |
| GO:0031929 | TOR signaling | BiologicalProcess |
| HP:0031377 | Abnormal cell proliferation | PhenotypicFeature |
| MESH:D002292 | Renal cell carcinoma | Disease |
|------------|------|---------|

## Relationships

|---------|-----------|---------|
| Subject | Predicate | Object  |
|---------|-----------|---------|
| Sirolimus | DECREASES ACTIVITY OF | Serine/Threonine-Protein Kinase Mtor |
| Serine/Threonine-Protein Kinase Mtor | POSITIVELY REGULATES | Tor Signaling |
| Tor Signaling | POSITIVELY CORRELATED WITH | Abnormal Cell Proliferation |
| Abnormal Cell Proliferation | CAUSES | Renal Cell Carcinoma |
|---------|-----------|---------|

Reference: 
  - [https://go.drugbank.com/drugs/DB00877](https://go.drugbank.com/drugs/DB00877)
